Please login to the form below
Hypertrophic cardiomyopathy
This page shows the latest Hypertrophic cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.
SOLVE FSHD announces the appointment of Dr Eva Chin as its executive director
SMA), myasthenia gravis and hypertrophic cardiomyopathy.
Latest news
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which
-
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
The US Food and Drug Administration (FDA) is set to review Bristol Myers Squibb’s (BMS) investigational candidate mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a
-
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
As part of the merger, BMS has now gained the rights to MyoKardia’s investigational treatment mavacamten, which is currently in development for obstructive hypertrophic cardiomyopathy (HCM).
-
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
In the process, BMS will gain the rights to MyoKardia’s investigational treatment mavacamten, which is currently being developed as a treatment for obstructive hypertrophic cardiomyopathy (HCM), wherein the wall between
-
Sanofi licenses cardiomyopathy programme in $200m deal
Sanofi has licensing rights to three of MyoKardia's programmes in the two most common inherited cardiomyopathies, including two projects looking at hypertrophic cardiomyopathy (HCM) and one focusing on dilated cardiomyopathy ... MyoKardia's approach
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
For a registry study, Novartis asked patients to complete the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which tracks physical limitations, symptom frequency, social limitation and quality of life. ... MyoKardia is gathering PROs in its
-
Pharma deals during September 2014
Myokardia will develop two HCM (hypertrophic cardiomyopathy) programmes where it retains US commercialisation rights and Sanofi has ex-US rights; and a third DCM (dilated cardiomyopathy) programme will be developed by
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Jonathan Fox leaves AstraZeneca for MyoKardia
MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Sanofi halts recruitment for trials assessing MS treatment
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- A creative awakening – how pharma is bringing innovation to the patient journey
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
